0001706226-19-000004.txt : 20190327
0001706226-19-000004.hdr.sgml : 20190327
20190327160803
ACCESSION NUMBER: 0001706226-19-000004
CONFORMED SUBMISSION TYPE: SC 13G/A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20190327
DATE AS OF CHANGE: 20190327
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: AYTU BIOSCIENCE, INC
CENTRAL INDEX KEY: 0001385818
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 470883144
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-88813
FILM NUMBER: 19708477
BUSINESS ADDRESS:
STREET 1: 373 INVERNESS PARKWAY
STREET 2: SUITE 206
CITY: ENGLEWOOD
STATE: CO
ZIP: 80112
BUSINESS PHONE: (720) 437-6580
MAIL ADDRESS:
STREET 1: 373 INVERNESS PARKWAY
STREET 2: SUITE 206
CITY: ENGLEWOOD
STATE: CO
ZIP: 80112
FORMER COMPANY:
FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC.
DATE OF NAME CHANGE: 20150609
FORMER COMPANY:
FORMER CONFORMED NAME: Rosewind CORP
DATE OF NAME CHANGE: 20070110
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Galileo Partners, LLC
CENTRAL INDEX KEY: 0001706226
IRS NUMBER: 260275299
FILING VALUES:
FORM TYPE: SC 13G/A
BUSINESS ADDRESS:
STREET 1: 1063 GAYLEY AVE
STREET 2: SECOND FLOOR
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
BUSINESS PHONE: 3102082225
MAIL ADDRESS:
STREET 1: 1063 GAYLEY AVE
STREET 2: SECOND FLOOR
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
SC 13G/A
1
20190326_AYTU_Ind.txt
SCHEDULE 13-G AMENDMENT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)* *
Aytu BioScience, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
054754700
(CUSIP Number)
March 20, 2019
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
__________
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall
not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
CUSIP No.
054754700
1. NAME OF REPORTING PERSONS
Howard Deshong, III
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) [_]
(b) [X]
3.SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
USA
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5. SOLE VOTING POWER
400,000
6. SHARED VOTING POWER
218,283
7. SOLE DISPOSITIVE POWER
400,000
8. SHARED DISPOSITIVE POWER
218,283
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
618,283
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS)
[_]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.9
12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
CUSIP No.
054754700
Item 1.
(a). Name of Issuer:
Aytu BioScience, Inc.
(b). Address of issuer's principal executive offices:
373 Inverness Parkway, Suite 206
Englewood, Colorado 80112
Item 2.
(a). Name of person filing:
Howard Deshong, III
(b). Address or principal business office or, if none, residence:
Galileo Partners, LLC
1033 Gayley Ave, Ste 204
Los Angeles, CA 90024
(c). Citizenship:
USA
(d). Title of class of securities:
Common Stock
(e). CUSIP No.:
054754700
Item 3. If This Statement is filed pursuant to Section 240.13d-1(b) or
240.13d-2(b), or (c), check whether the person filing is a
(a) [_] Broker or dealer registered under section 15 of the
Act (15 U.S.C. 78o).
(b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [_] Insurance company as defined in section 3(a)(19) of the
Act (15 U.S.C. 78c).
(d) [_] Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8).
(e) [_] An investment adviser in accordance with
Section 240.13d-1(b)(1)(ii)(E);
(f) [_] An employee benefit plan or endowment fund in accordance with
Section 240.13d-1(b)(1)(ii)(F);
(g) [_] A parent holding company or control person in accordance with
Section 240.13d-1(b)(1)(ii)(G);
(h) [_] A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C.1813);
(i) [_] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C. 80a-3);
(j) [_] A non-U.S. institution in accordance with
Section 240.13d-1(b)(1)(ii)(J);
(k) [_] Group, in accordance with Section 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with
Section 240.13d-1(b)(1)(ii)(J), please specify the type of
institution:
Item 4. Ownership. Provide the following information regarding the aggregate
number and percentage of the class of securities of the issuer
identified in Item 1.
(a) Amount beneficially owned:
618,283
(b) Percent of class:
4.9
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
400,000
(ii) Shared power to vote or to direct the vote
218,283
(iii) Sole power to dispose or to direct the disposition of
400,000
(iv) Shared power to dispose or to direct the disposition of
218,283
As calculated in accordance with Rule 13d-3 of the Securities Exchange Act
of 1934, as amended, Howard Deshong, III (the Filer) beneficially owns
618,283 shares of the Issuer's common stock (Common Stock), representing
approximately 4.9% of such class of shares outstanding. The Filer owns
250,904 shares, representing approximately 2%, of Common Stock outright;
89,500 of which the Filer owns directly and 161,404 that the filer owns
in his capacities as managing member of the general partner of Galileo
Partners Fund I, L.P., a Delaware limited partnership, and as trustee
of the Howard C. Deshong, III Revocable Trust. The Filer also has the
right to acquire a total of 367,379 Common Shares within 60 days due
to his direct and indirect ownership of certain warrants and other
convertible securities.
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities, check the following [X].
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company or Control Person.
Not applicable
Item 8. Identification and Classification of Members of the Group.
Not applicable
Item 9. Notice of Dissolution of Group.
Not applicable
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose
or effect, other than activities solely in connection with a nomination
under s.240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.
March 27, 2019
(Date)
Howard Deshong, III
By: /s/ Howard Deshong
Name: Howard Deshong
Title: Self
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is
signed on behalf of a person by his authorized representative other than an
executive officer or general partner of the filing person, evidence of the
representative's authority to sign on behalf of such person shall be filed
with the statement, provided, however, that a power of attorney for this
purpose which is already on file with the Commission may be incorporated by
reference. The name and any title of each person who signs the statement
shall be typed or printed beneath his signature.
Note. Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See s.240.13d-7 for
other parties for whom copies are to be sent.
Attention. Intentional misstatements or omissions of fact constitute
Federal criminal violations (see 18 U.S.C. 1001).